Skip to main content
ZTS
NYSE Life Sciences

Zoetis Slashes 2026 EPS Outlook to $6.35-$6.50

feedReported by Dow Jones Newswires
Sentiment info
Negative
Importance info
8
Price
$103
Mkt Cap
$46.77B
52W Low
$110.94
52W High
$172.23
Market data snapshot near publication time

summarizeSummary

Zoetis Inc. has significantly lowered its earnings per share (EPS) guidance for fiscal year 2026 to a range of $6.35 to $6.50. This revised outlook represents a material reduction in the company's financial expectations, following its strong 2025 results reported in February. The downward revision is a negative catalyst, likely to pressure the stock, especially given its current proximity to 52-week lows. Professional traders will need to reassess valuation models and monitor for further commentary on the underlying drivers of this reduced forecast.

At the time of this announcement, ZTS was trading at $103.00 on NYSE in the Life Sciences sector, with a market capitalization of approximately $46.8B. The 52-week trading range was $110.94 to $172.23. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.


show_chartPrice Chart

Share this article

Copied!

feed ZTS - Latest Insights

ZTS
May 07, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
ZTS
May 07, 2026, 7:04 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
ZTS
Apr 08, 2026, 9:01 AM EDT
Filing Type: DEF 14A
Importance Score:
7
ZTS
Feb 12, 2026, 4:49 PM EST
Filing Type: 10-K
Importance Score:
8
ZTS
Feb 12, 2026, 7:04 AM EST
Filing Type: 8-K
Importance Score:
7